Elevance Health Inc. (ELV)

Executive Summary / Key Takeaways

• Elevance Health is deliberately prioritizing margin discipline over membership growth across its core Health Benefits segment, positioning 2026 as a transition year with Medicaid margins at -1.75% and Medicare Advantage membership down high-teens, setting the stage for sustainable profitability recovery in 2027 and beyond.

• The Carelon platform (Rx and Services) is emerging as a powerful diversification engine, with Services revenue growing 57.7% in 2025 through acquisitions and risk-based capabilities, creating a less membership-dependent, higher-margin business that will drive the majority of incremental profit growth through 2027.

• Technology investments in AI and HealthOS (88,000+ providers, 1,200 organizations) are strategic differentiators that reduce administrative burden by 68% and enable real-time care decisions, directly supporting margin recovery by bending the medical cost curve.

• Despite generating $4.29 billion in operating cash flow and delivering 13.25% ROE that exceeds UnitedHealth's (UNH) 12.54%, ELV trades at 11.56x earnings—a 45% discount to UNH's 20.83x—creating asymmetric risk/reward if management executes on its margin reset strategy.

• The critical variable for investors is the pace of Medicaid rate alignment with elevated acuity and utilization; while management expects improvement in 2H 2025 and beyond, any further delays would extend the margin trough and pressure the 2027 recovery thesis.

Setting the Scene: From Anthem to Integrated Health Platform

Elevance Health, originally incorporated as Anthem, Inc. on July 17, 2001, has evolved from a traditional health insurer into a vertically integrated health solutions platform. Headquartered in Indianapolis, Indiana, the company serves approximately 45.2 million medical members and 118 million total consumers across its four operating segments. This transformation fundamentally changes how Elevance captures value—not just through underwriting spreads, but by owning more of the care delivery and pharmacy management stack.

The industry structure is concentrated, with the top five players controlling over 50% of national markets. Elevance holds a 12% market share, positioning it as a clear #2 behind UnitedHealth's 16% but ahead of Cigna (CI), Humana (HUM), and Centene (CNC). This scale provides essential negotiating leverage with providers and drug manufacturers, but the real moat lies in Elevance's exclusive Blue Cross Blue Shield licenses across 14 states. These licenses create regional dominance that national competitors cannot easily replicate, translating into higher retention rates and pricing power in core markets.

The broader market faces headwinds. Medical cost trends are running at twice historical averages, driven by pent-up demand post-pandemic, GLP-1 drug proliferation, and aggressive provider coding practices that inflate unit costs. Simultaneously, regulatory shifts—the expiration of ACA premium subsidies, Medicaid redeterminations, and Medicare Advantage funding pressures—are reshaping membership pools and risk profiles. These forces represent structural changes that will separate disciplined operators from those chasing top-line growth at any cost.

Technology and Strategic Differentiation: The AI-Enabled Cost Curve

Elevance's technology strategy centers on HealthOS, a digital platform that by Q1 2025 supported over 88,000 care providers and 1,200 provider organizations. The platform's power lies in its ability to enable real-time decision-making and seamless prior authorizations, eliminating requirements for more than 400 outpatient procedures for high-performing providers. Each eliminated prior auth reduces administrative friction by approximately $15-25 per transaction while accelerating care delivery—a direct hit to the 2-3% of premium dollars typically wasted on administrative complexity.

The OpenAI partnership announced in Q4 2025 represents a significant operational shift. Management is training associates to deploy AI responsibly at scale, with a virtual assistant launching for over 10 million members. The economic impact is tangible: HealthOS has reduced denials by more than 68% and peer-to-peer reviews by over 100%, directly lowering the operating expense ratio to 10.5% in 2025. This 60 basis point improvement year-over-year demonstrates that technology investments are converting into operational leverage.

Value-based care models provide another differentiation layer. The oncology program, which reduced inpatient admissions and improved treatment adherence in commercial markets, is expanding to Medicare Advantage in 2025. These arrangements drive nearly $100 in per member per month savings across medical and pharmacy costs. Elevance is not just managing costs but fundamentally restructuring provider incentives to align with outcomes, creating a sustainable cost advantage that fee-for-service competitors cannot match.

Financial Performance: Margin Pain as Evidence of Discipline

The 2025 financial results show a story of deliberate sacrifice. Health Benefits segment revenue grew 11.2% to $167.1 billion, yet operating gain declined 33.4% to $4.2 billion, driving margins from 4.2% to 2.5%. This reflects strategic repositioning. Management increased premium yields across all lines to reflect true medical cost trends, accepting near-term margin compression to avoid the death spiral of underpricing. The alternative is to chase membership with inadequate pricing and watch margins evaporate when costs inevitably outpace premiums.

CarelonRx delivered 20.7% revenue growth to $43.4 billion with operating gain up 11.3% to $2.4 billion. The margin compression from 6.0% to 5.6% reflects deliberate investments in specialty pharmacy infrastructure, including the BioPlus platform migration and Kroger Specialty Pharmacy integration. Specialty drugs represent 50% of pharmacy spending but only 2% of scripts. Owning the specialty channel provides pricing power and data insights that third-party PBMs cannot offer, positioning CarelonRx to capture a growing share of the $260 billion specialty market.

Carelon Services is the standout, with revenue surging 57.7% to $28.3 billion and operating gain up 33.9% to $960 million. The margin decline from 4.0% to 3.4% reflects the December 2024 CareBridge acquisition and expanded risk arrangements that carry upfront setup costs but generate durable, recurring revenue. Excluding internal membership headwinds, organic growth was in the high teens to low twenties. This segment now serves 91.8 million consumers, nearly double the medical membership base, proving that Elevance can monetize its capabilities beyond traditional insurance.

The consolidated picture reveals a company in transition. Operating cash flow of $4.29 billion was impacted by the $666 million BCBSA provider settlement payment and working capital timing, yet still represented 0.8x net income. The parent company holds $2.57 billion in liquid assets, and the debt-to-capital ratio improved to 42.1% from 43%. With $6.7 billion remaining in buyback authorization, management has ample firepower to be opportunistic—CFO Mark Kaye explicitly stated the stock trades well below intrinsic value.

Outlook and Execution: The 2026 Trough Thesis

Management's 2026 guidance of at least $25.50 in adjusted EPS represents a 15% decline from 2025's $30, but the baseline is crucial. The 2025 result included $3.75 per share in nonrecurring tax benefits; the true operational baseline was $26.25. The guided $25.50 therefore represents a modest operational decline of approximately 2.9%, rather than a collapse. This indicates management is providing realistic, achievable targets.

The segment-level guidance reveals the deliberate reset strategy. Medicaid margins will trough at -1.75% in 2026 as rates lag elevated acuity and utilization that runs at twice historical trends. However, composite rate increases in the mid-single-digit range are already locked in for January 2026, with further adjustments expected for the July cohort. Margin recovery is a matter of timing, not structural impairment. Elevance is waiting for states to incorporate current experience into rates while using the Carelon platform to manage acuity through better care coordination.

Medicare Advantage membership will decline in the high-teens percentage range as Elevance exits 1-star and 2-star plans that cannot achieve sustainable economics. The remaining membership will be concentrated in 4-star or higher contracts, which rise from 40% to 55% of the book for payment year 2027. The margin improvement to at least 2% in 2026, up from breakeven, demonstrates that quality over quantity generates superior returns. This positions Elevance to benefit from any future rate increases without the drag of unprofitable volume.

The commercial business shows healthy momentum, winning 9 of 11 "second Blue" bids for 2026—a process created by the BCBSA settlement that allows national accounts to solicit competing Blue plan bids. This proves Elevance can compete head-to-head and win even when incumbency is stripped away. The expected high single-digit membership decline reflects deliberate pricing decisions, particularly in lower-margin public sector business, prioritizing margin stability over top-line growth.

Carelon's outlook reinforces its importance. Near-term growth will be moderated by lower health plan membership, but the external revenue base provides insulation. CarelonRx's 20% growth in Q3 2025 came from scaling specialty assets with largest clients, while Carelon Services' 50%+ growth was driven by CareBridge integration and risk-based capabilities. The long-term margin target of mid-single-digits for both Carelon segments, combined with Health Benefits, supports the enterprise-wide 5-6% margin target.

Competitive Positioning: The Valuation Discount Anomaly

Elevance's competitive positioning reveals a striking anomaly. Against UnitedHealth, Elevance generates higher ROE (13.25% vs 12.54%) and operates with lower leverage (debt-to-equity 0.74 vs 0.82), yet trades at a significant discount in earnings multiples (11.56x vs 20.83x). The EV/Revenue multiple of 0.31x is less than half UNH's 0.68x. This discount persists despite Elevance's margin profile in core operations and its emerging Carelon growth engine.

The comparison with Cigna is equally revealing. While Cigna's P/E of 11.85x is similar, its operating margin of 3.53% is achieved through a more concentrated portfolio with higher exposure to employer market cyclicality. Elevance's diversified mix across commercial, Medicare, Medicaid, and now Carelon services provides better earnings stability. Cigna's growth relies heavily on PBM scale, whereas Elevance is building integrated care capabilities that address the root causes of cost inflation.

Humana's struggles highlight Elevance's strategic wisdom. Humana's operating margin of -1.79% and ROE of 7.04% reflect its over-concentration in Medicare Advantage during a period of funding pressure and utilization spikes. Elevance's deliberate MA retrenchment, while impacting membership, avoids the margin collapse Humana is experiencing. The diversified portfolio means that Medicaid headwinds are partially offset by commercial pricing power and Carelon growth.

Centene's thin margins (operating margin -1.88%, ROE -28.68%) demonstrate the risks of pure-play Medicaid focus. Elevance's Medicaid challenges are real—2025 margins are expected at -50 basis points—but the company has the balance sheet strength and diversified earnings to weather the storm while working with states on rate adjustments. Centene's lack of commercial cross-subsidy leaves it exposed to Medicaid rate fluctuations with no ability to offset through other segments.

The technology comparison favors Elevance's integrated approach. While UNH's Optum is more mature, Elevance's HealthOS platform is scaling faster in terms of provider adoption, and the OpenAI partnership positions it at the forefront of generative AI in healthcare. This matters because the next wave of cost management will be won by companies that can use AI to predict and prevent high-cost events, not just process claims more efficiently.

Risks and Asymmetries: What Could Break the Thesis

The primary risk is that Medicaid rate alignment takes longer than the anticipated 12-18 months. States face budget pressures and political constraints that could delay rate increases even as acuity and utilization remain elevated. If the -1.75% Medicaid margin trough extends into 2027, the 12% EPS growth recovery thesis fails. Every 100 basis points of Medicaid margin pressure translates to approximately $0.50 in EPS, given the segment's scale. With 10 million Medicaid members, even modest delays in rate recovery have material impact.

ACA market deterioration presents a second-order risk. If enhanced premium subsidies expire and the risk pool becomes more acute, competitors could engage in destructive pricing to retain members, pressuring Elevance's disciplined approach. The company is guiding to 900,000 ACA members by end-2026, down from current levels, but if the market contracts more severely or if the remaining population's morbidity exceeds the 2x ER utilization currently observed, pricing assumptions could prove optimistic.

Medicare Advantage funding stability is a macro risk beyond management's control. If CMS continues to underfund the program relative to utilization trends, even Elevance's quality-focused portfolio will face margin pressure. The company's ability to exit unprofitable geographies provides some protection, but a broad-based rate cut would delay the 2%+ margin target for the segment.

On the positive side, Carelon could deliver upside asymmetry. If the CareBridge integration accelerates and external payer relationships deepen faster than expected, Carelon Services could exceed its mid-single-digit margin target while growing in the high-teens organically. The oncology value-based care model expanding to Medicare Advantage could generate savings beyond the $100 PMPM already achieved, creating a competitive moat that drives share gains when competitors are retrenching.

Valuation Context: Pricing for Failure, Not Recovery

At $291.48 per share, Elevance trades at 11.56x trailing earnings and 0.32x sales. The free cash flow yield of approximately 5% provides a floor valuation that assumes minimal growth. This pricing reflects market skepticism about the margin recovery timeline.

The EV/EBITDA multiple of 6.74x compares favorably to UNH's 14.11x and CI's 7.71x, suggesting the market is pricing Elevance as a lower-quality operator despite superior ROE and comparable balance sheet strength. The price-to-book ratio of 1.47x sits between UNH's 2.65x and CNC's 0.85x, reflecting uncertainty about asset quality during the margin reset.

This valuation leaves significant room for re-rating if management executes. A return to the historical enterprise margin target of 5-6% would support a 15x earnings multiple, implying 30% upside from current levels even without multiple expansion. If Carelon's growth trajectory accelerates and justifies a sum-of-the-parts valuation, the gap to UNH's multiple could narrow, providing 50%+ upside potential.

The balance sheet supports this thesis. With $37.2 billion in cash and investments, a 42.1% debt-to-capital ratio, and $6.7 billion in buyback authorization, Elevance has the financial flexibility to be opportunistic. The $2.1 billion in expected subsidiary dividends for 2026 provides parent-level liquidity to fund buybacks without impairing subsidiary capital ratios—a structural advantage that supports the capital allocation shift toward shareholder returns.

Conclusion: A Deliberate Reset with Asymmetric Payoff

Elevance Health is actively reshaping its portfolio to thrive in a structurally changed environment. The 2026 margin trough—driven by Medicaid rate lag, ACA repositioning, and Medicare Advantage retrenchment—represents a deliberate choice to prioritize sustainability over scale. This strategy distinguishes Elevance from competitors experiencing forced margin collapse or lacking diversification to weather the storm.

The Carelon acceleration provides the growth engine that makes this reset possible. With Services revenue growing 57.7% and expanding external relationships, Elevance is building a platform business that monetizes capabilities beyond traditional insurance. The technology investments in AI and HealthOS are current tools bending the cost curve today.

The valuation discount to peers appears significant given superior ROE, strong cash generation, and a clear path to margin recovery. The critical variable remains Medicaid rate alignment—if states incorporate current experience into rates as expected, the 2027 return to 12% EPS growth is achievable. If delayed, the downside is cushioned by Carelon's growth and the balance sheet strength.

For investors, Elevance offers an asymmetric risk/reward profile: limited downside given the 5% free cash flow yield and strong balance sheet, with 30-50% upside if margin recovery materializes. The story will be decided by execution on the deliberate strategy already in motion.